The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions;Die wertigkeit der fluordeoxyglukose positronenemissionstomographie (FDG-PET) in der diagnostik von pankreasprozessen

Zentralblatt fur Chirurgie

Volumn 128, Issue 5, 2003, Pages 375-378

  Voth, Matthias ^a   Opfermann, T ^a   Gottschild, D ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

FDG PET; Glucose metabolism; Pancreatic cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE;

BENIGN TUMOR; CANCER PATIENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GLUCOSE METABOLISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACTIVATION; PANCREAS CANCER; PANCREAS DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; PANCREATITIS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0038544274     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40030     Document Type: Review

References (28)

1. Bakkevold KE, Kambestad B. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - the prognostic factors influencing the long-term results. A prospective multicentre study. Eur J Surg Oncol 1993; 19 (2): 147-161
2. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Büll U. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma]. Radiologe 1996; 36 (5): 435-440
3. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C, Büll U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192 (1): 79-86
4. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40 (11): 1784-1791
5. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39 (6): 1030-1033
6. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, Beger HG, Reske SN. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20 (2): 109-116
7. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37 (3): 441-446
8. Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, Buchler MW. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36 (5): 771-777
9. Fröhlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999; 40 (2): 250-255
10. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, Berger MR, Altmann A, van Kaick G. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994: 21 (6): 827-834
11. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996; 20 (3): 363-369
12. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, Schiepers C, Choi Y, Rege S, Nitzsche E et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17 (4): 582-589
13. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, Kajiyama T, Ohshio G, Imamura M, Konishi J. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195 (2): 345-352
14. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001; 26 (3): 254-259
15. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, Isomura T, Ito S, Nishino M, Ishigaki T. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995; 22 (1): 32-39
16. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, Coleman RE. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998; 171 (6): 1565-1570
17. Klever P, Bares R, Fass J, Büll U, Schumpelick V. PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 1992; 340 (8828): 1158-1159
18. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89 (12): 2547-2554
19. Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, Imdahl A. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002; 29 (2): 237-242
20. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger HG. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38 (9): 1344-1348
21. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28 (11): 1707-1723
22. Schek N, Hall BL, Finn OJ. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res 1988; 48 (22): 6354-6359
23. Schober O, Lottes G. [Positron emission tomography and radiation exposure]. Nuklearmedizin 1994; 33 (5):174-177
24. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25 (3): 259-264
25. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195 (2): 339-344
26. van Gulik TM, Moojen TM, van Geenen R, Rauws EA, Obertop H, Gouma DJ. Differential diagnosis of focal pancreatitis and pancreatic cancer. Ann Oncol 1999; 10 (Suppl 4): 85-88
27. Warburg O. On the origin of cancer cells. Science 1956; 123-309
28. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Büll U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24 (6): 678-682